Equities Analysts Offer Predictions for Monopar Therapeutics Inc.’s Q1 2024 Earnings (NASDAQ:MNPR)

Monopar Therapeutics Inc. (NASDAQ:MNPRFree Report) – Equities researchers at Brookline Capital Management issued their Q1 2024 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Monday, April 1st. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($0.68) per share.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $0.64 on Tuesday. The company has a market capitalization of $9.52 million, a PE ratio of -1.05 and a beta of 1.19. Monopar Therapeutics has a one year low of $0.27 and a one year high of $1.75. The business has a 50 day simple moving average of $0.65 and a 200 day simple moving average of $0.50.

Hedge Funds Weigh In On Monopar Therapeutics

A hedge fund recently bought a new stake in Monopar Therapeutics stock. Windsor Advisory Group LLC bought a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPRFree Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 89,974 shares of the company’s stock, valued at approximately $56,000. Windsor Advisory Group LLC owned 0.64% of Monopar Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

See Also

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.